Stay updated on Empagliflozin in Heart Failure Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin in Heart Failure Clinical Trial page.

Latest updates to the Empagliflozin in Heart Failure Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedA new site revision, v3.4.2, was added and the previous revision v3.4.1 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1, a minor platform update with no changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page now displays a glossary toggle and adds a 'Last Update Submitted that Met QC Criteria' label, as well as a 'No FEAR Act Data' notice with Revision: v3.4.0. The older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and Revision: v3.3.4 have been removed.SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no observable changes to study details or layout.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a Locations section with the Connecticut site for the EMPA trial and removed the HHS Vulnerability Disclosure footer link and the older Connecticut Locations listing.SummaryDifference0.2%

Stay in the know with updates to Empagliflozin in Heart Failure Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin in Heart Failure Clinical Trial page.